iSPERSE is a novel inhaled dry powder delivery platform developed by Pulmatrix for use in the delivery of drugs via inhalation for local or systemic applications.
The preclinical data of iSPERSE suggested that it can efficiently deliver consistent double- and triple-combination drug doses and offers improved drug efficacy and safety for patients having both normal and lower or impaired lung function.
In the in vitro and preclinical studies, an iSPERSE fluticasone and salmeterol combination was matched to commercially available Advair Diskus, which contains the fluticasone and salmeterol combination blended with lactose to enable pulmonary delivery.
iSPERSE demonstrated improved delivery efficiency over Advair Diskus, as iSPERSE was shown to deliver over 2 times more lung dose of the active pharmaceutical ingredients than Advair Diskus.
In addition, iSPERSE behaved flow rate independently at flow rates of 28.3 and 60.0 LPM, maintaining a similar fine particle fraction when tested via actuation from a capsule-based passive dry powder inhaler.